We are live on ! Find out more
BPMC

Blueprint Medicines
BPMC

Delisted

BPMC was delisted on the 17th of July, 2025.

Back to rankings

219 hedge funds and large institutions have $3.78B invested in Blueprint Medicines in 2019 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 87 increasing their positions, 56 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

209% more call options, than puts

Call options by funds: $90.8M | Put options by funds: $29.4M

55% more repeat investments, than reductions

Existing positions increased: 87 | Existing positions reduced: 56

3.21% more ownership

Funds ownership: 101.52% → 104.73% (+3.2%)

0% more funds holding in top 10

Funds holding in top 10: 8 → 8 (0)

0% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 29

0% less funds holding

Funds holding: 220 → 219 (-1)

19% less capital invested

Capital invested by funds: $4.68B → $3.78B (-$898M)

Holders
219
Holders Change
-1
Holders Change %
-0.45%
% of All Funds
4.8%
Holding in Top 10
8
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.18%
New
29
Increased
87
Reduced
56
Closed
29
Calls
$90.8M
Puts
$29.4M
Net Calls
+$61.4M
Net Calls Change
+$37.8M

Top Buyers

Rank Fund Capital Flow
1
CCM
Cadian Capital Management
New York
+$77.4M
2
Viking Global Investors
Viking Global Investors
Connecticut
+$21.7M
3
Westfield Capital Management
Westfield Capital Management
Massachusetts
+$20.3M
4
HM
HealthCor Management
New York
+$19.6M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$18.2M

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$28.5M
2
Invesco
Invesco
Georgia
-$24.3M
3
Wellington Management Group
Wellington Management Group
Massachusetts
-$21.1M
4
AG
Artal Group
Luxembourg
-$13M
5
Federated Hermes
Federated Hermes
Pennsylvania
-$12.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
Citigroup
101
Citigroup
New York
$2.01M -$3.97M -45,926 -63%
Legal & General Group
102
Legal & General Group
United Kingdom
$1.96M +$299K +3,458 +15%
Dimensional Fund Advisors
103
Dimensional Fund Advisors
Texas
$1.88M +$1.41M +16,318 +177%
JG
104
Jefferies Group
New York
$1.87M +$1.16M +13,428 +112%
State Board of Administration of Florida Retirement System
105
State Board of Administration of Florida Retirement System
Florida
$1.82M – – –
NC
106
NBW Capital
Massachusetts
$1.78M -$82.6K -956 -4%
CIP
107
Chartwell Investment Partners
Pennsylvania
$1.75M – – –
Bank of Montreal
108
Bank of Montreal
Ontario, Canada
$1.74M +$319K +3,694 +18%
Neuberger Berman Group
109
Neuberger Berman Group
New York
$1.65M -$527K -6,100 -21%
MIM
110
MetLife Investment Management
New Jersey
$1.6M – – –
ProShare Advisors
111
ProShare Advisors
Maryland
$1.47M +$84.1K +973 +5%
SGH
112
Sivik Global Healthcare
Connecticut
$1.47M -$864K -10,000 -33%
Los Angeles Capital Management
113
Los Angeles Capital Management
California
$1.43M -$155K -1,790 -8%
MAP
114
Moody Aldrich Partners
Massachusetts
$1.42M +$1.66M +19,258 New
CA
115
CHI Advisors
New York
$1.32M +$1.56M +18,000 New
Comerica Bank
116
Comerica Bank
Texas
$1.3M +$515K +5,961 +54%
IBT
117
International Biotechnology Trust
United Kingdom
$1.25M – – –
FP
118
Foundry Partners
Minnesota
$1.25M +$70.2K +812 +5%
MLICM
119
Metropolitan Life Insurance Company (MetLife)
New York
$1.17M +$93.2K +1,078 +7%
BG
120
Bellevue Group
Switzerland
$1.16M +$25.9K +300 +2%
Principal Financial Group
121
Principal Financial Group
Iowa
$1.05M +$118K +1,369 +11%
PIM
122
Platinum Investment Management
Australia
$936K – – –
TRSOTSOK
123
Teachers Retirement System of the State of Kentucky
Kentucky
$920K – – –
PA
124
Profund Advisors
Maryland
$906K +$1.07M +12,329 New
QSS
125
Quantitative Systematic Strategies
Florida
$830K +$64.8K +750 +7%
3 4
5
6 7

BPMC Hedge Fund Activity: Q3 2019 in Review

219 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q3 2019, worth a combined $3.78B — down 19% from $4.68B a quarter earlier.

Fund positioning in BPMC was balanced in Q3 2019: 29 funds opened new positions, 29 closed out, 87 added to existing stakes and 56 trimmed.

The largest buyer was Cadian Capital Management, adding an estimated $77.4M. The largest seller was Perceptive Advisors, cutting an estimated $28.5M.

  • 219 institutional investors held Blueprint Medicines (BPMC) as of Q3 2019, down from 220 in Q2 2019.
  • Funds reported $3.78B of Blueprint Medicines stock for Q3 2019, down 19% quarter-over-quarter.
  • 29 funds opened new Blueprint Medicines positions in Q3 2019 and 29 closed out, a net change of 0 holders.
  • The largest Blueprint Medicines buyer in Q3 2019 was Cadian Capital Management, an estimated $77.4M added.
  • The largest Blueprint Medicines seller in Q3 2019 was Perceptive Advisors, an estimated $28.5M sold.

Based on aggregated 13F filings for Q3 2019.